Aktuellt
SENASTE
Following the Q1 numbers, we have only made minor adjustments to our estimates but leave our long-term assumptions unchanged. Our fair valuation range (SEK 108-140 per share) is unchanged. With plenty of milestone events lined up in 2021, and the recent clinical data boding well for the first phase clinical study results (expected in Q3/21), our view on Fluoguide remains intact.
LÄS MER
